Effect of the thumbtack needle on gastrointestinal function recovery after laparoscopic radical gastrectomy for gastric cancer with the concept of enhanced recovery after surgery: a randomized controlled trial.
무작위 임상시험
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
103 participants were screened, and 80 were enrolled (40 per group).
I · Intervention 중재 / 시술
perioperative enhanced recovery after surgery management
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Thumbtack needle therapy at bilateral Neiguan (PC6), Zusanli (ST36), Shangjuxu (ST37), Hegu (LI4), and Sanyinjiao (SP6) is a safe and effective intervention that promotes early recovery of GI function after laparoscopic radical gastrectomy for gastric cancer. [CLINICAL TRIAL REGISTRATION] http://www.chictr.org.cn, ChiCTR2400084712.
[OBJECTIVES] Postoperative gastrointestinal (GI) dysfunction is a common complication in patients undergoing gastric cancer surgery.
- 95% CI -7.0 to -1.0
APA
Guo S, Lin XP, et al. (2025). Effect of the thumbtack needle on gastrointestinal function recovery after laparoscopic radical gastrectomy for gastric cancer with the concept of enhanced recovery after surgery: a randomized controlled trial.. Frontiers in surgery, 12, 1612766. https://doi.org/10.3389/fsurg.2025.1612766
MLA
Guo S, et al.. "Effect of the thumbtack needle on gastrointestinal function recovery after laparoscopic radical gastrectomy for gastric cancer with the concept of enhanced recovery after surgery: a randomized controlled trial.." Frontiers in surgery, vol. 12, 2025, pp. 1612766.
PMID
41050349 ↗
Abstract 한글 요약
[OBJECTIVES] Postoperative gastrointestinal (GI) dysfunction is a common complication in patients undergoing gastric cancer surgery. This study aimed to evaluate the effect of thumbtack needle therapy on GI function recovery after laparoscopic radical gastrectomy.
[METHODS] Participants were randomly assigned to either the treatment or control group. Both groups received perioperative enhanced recovery after surgery management. Participants in the treatment group received thumbtack needle therapy at bilateral Neiguan (PC6), Zusanli (ST36), Shangjuxu (ST37), Hegu (LI4), and Sanyinjiao (SP6). Primary outcomes included the time to bowel sound recovery and time to first flatus (all measured in hours). Secondary outcomes included the time to first defecation, time to removal of the nasogastric tube and intra-abdominal drains (all measured in hours), postoperative pain scores, nausea and vomiting scores, abdominal distension scores (all measured in points), length of hospital stay (days), incidence of complications (%), safety evaluation, and overall response rate (%).
[RESULTS] A total of 103 participants were screened, and 80 were enrolled (40 per group). Baseline characteristics were similar between groups. Compared with the control group, the treatment group showed significantly shorter times to bowel sound recovery (difference, -4.0 h, 95% CI: -7.0 to -1.0, = 0.010), first flatus (-11.0 h, 95% CI: -19.0 to -2.0, = 0.017), first defecation (-8.0 h, 95% CI: -16.0 to -1.0, = 0.026), nasogastric tube removal (-12.0 h, 95% CI: -27.0 to -2.0 = 0.023), and intra-abdominal drain removal (-10.0 h, 95% CI: -21.0 to -1.0, = 0.038). Pain scores were significantly lower in the treatment group on postoperative day (POD) 1 (-1, 95% CI: -1 to 0, = 0.031), POD 2 (-1, 95% CI: -2 to -1, < 0.001), and POD 3 (-1, 95% CI: -2 to 0, < 0.001). Similar improvements were observed in nausea, vomiting, and abdominal distension scores on POD 1-3 (all showing a median difference of -1, all < 0.05). The treatment group also had a significantly shorter hospital stay (difference, -1.7 days, 95% CI: -3.0 to -0.3, 0.015). There was no significant difference in the incidence of postoperative complications (difference, -5.0%, 95% CI: -18.6 to 8.0, 0.396), and no adverse reactions occurred in the treatment group. The overall response rate was significantly higher in the treatment group (difference, 17.5%, 95% CI: 0.18-34.0, 0.046).
[CONCLUSION] Thumbtack needle therapy at bilateral Neiguan (PC6), Zusanli (ST36), Shangjuxu (ST37), Hegu (LI4), and Sanyinjiao (SP6) is a safe and effective intervention that promotes early recovery of GI function after laparoscopic radical gastrectomy for gastric cancer.
[CLINICAL TRIAL REGISTRATION] http://www.chictr.org.cn, ChiCTR2400084712.
[METHODS] Participants were randomly assigned to either the treatment or control group. Both groups received perioperative enhanced recovery after surgery management. Participants in the treatment group received thumbtack needle therapy at bilateral Neiguan (PC6), Zusanli (ST36), Shangjuxu (ST37), Hegu (LI4), and Sanyinjiao (SP6). Primary outcomes included the time to bowel sound recovery and time to first flatus (all measured in hours). Secondary outcomes included the time to first defecation, time to removal of the nasogastric tube and intra-abdominal drains (all measured in hours), postoperative pain scores, nausea and vomiting scores, abdominal distension scores (all measured in points), length of hospital stay (days), incidence of complications (%), safety evaluation, and overall response rate (%).
[RESULTS] A total of 103 participants were screened, and 80 were enrolled (40 per group). Baseline characteristics were similar between groups. Compared with the control group, the treatment group showed significantly shorter times to bowel sound recovery (difference, -4.0 h, 95% CI: -7.0 to -1.0, = 0.010), first flatus (-11.0 h, 95% CI: -19.0 to -2.0, = 0.017), first defecation (-8.0 h, 95% CI: -16.0 to -1.0, = 0.026), nasogastric tube removal (-12.0 h, 95% CI: -27.0 to -2.0 = 0.023), and intra-abdominal drain removal (-10.0 h, 95% CI: -21.0 to -1.0, = 0.038). Pain scores were significantly lower in the treatment group on postoperative day (POD) 1 (-1, 95% CI: -1 to 0, = 0.031), POD 2 (-1, 95% CI: -2 to -1, < 0.001), and POD 3 (-1, 95% CI: -2 to 0, < 0.001). Similar improvements were observed in nausea, vomiting, and abdominal distension scores on POD 1-3 (all showing a median difference of -1, all < 0.05). The treatment group also had a significantly shorter hospital stay (difference, -1.7 days, 95% CI: -3.0 to -0.3, 0.015). There was no significant difference in the incidence of postoperative complications (difference, -5.0%, 95% CI: -18.6 to 8.0, 0.396), and no adverse reactions occurred in the treatment group. The overall response rate was significantly higher in the treatment group (difference, 17.5%, 95% CI: 0.18-34.0, 0.046).
[CONCLUSION] Thumbtack needle therapy at bilateral Neiguan (PC6), Zusanli (ST36), Shangjuxu (ST37), Hegu (LI4), and Sanyinjiao (SP6) is a safe and effective intervention that promotes early recovery of GI function after laparoscopic radical gastrectomy for gastric cancer.
[CLINICAL TRIAL REGISTRATION] http://www.chictr.org.cn, ChiCTR2400084712.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Discovery of novel 2-azabicyclo[3.2.1]octane derivatives against non-small cell lung cancer from aconitine simplification.
- Hsa_circ_0003176: a key player in the m6A modification-mediated regulation of autophagy and glycolysis in cisplatin-resistant non-small cell lung cancer.
- Ferroptosis in reproductive system disorders: Pathological roles and therapeutic potential.
- Bufalin Inhibits the PI3K/AKT Pathway by Targeting GTF3C4 to Impede Breast Cancer Progression.
- Emerging frontiers in microRNA technology: Innovations driving precision medicine.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Safe discharge on the second postoperative day after major colorectal surgery: a decision-making strategy based on quantitative serological data.
- Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in -amplified gastric cancer.
- Association of preoperative frailty and prognostic nutritional index with postoperative delirium in elderly gastric cancer patients: A single-center observational study.
- Low serum pseudocholinesterase levels are associated with mortality in patients with hepatocellular carcinoma.
- Complete response to Nivolumab-based chemotherapy in a case of advanced gastric cancer with multiple immune-related adverse events.